Search for: "Grant v. Bristol-Myers Squibb"
Results 41 - 60
of 157
Sorted by Relevance
|
Sort by Date
26 Apr 2007, 9:28 am
(c) is the fourth condition set out in Bristol-Myers Squibb and Others, namely that the presentation of the repackaged product is not such as to be liable to damage the reputation of the trade mark or its owner, only infringed if the packaging is defective, of poor quality or untidy or does it extend to anything which damages the reputation of the trade mark? [read post]
28 Sep 2010, 3:14 pm
Par Pharmaceutical Companies, Inc. et al (Patent Docs) Baraclude (Entecavir) – US: Patent infringement complaint filed following Paragraph IV certification: Bristol-Myers Squibb Co. v. [read post]
25 Apr 2007, 5:43 pm
Following Bristol-Myers Squibb Co. v. [read post]
29 Jul 2013, 2:24 am
Unfortunately,without any thumbs, he was unable to forwardthem to the true recipient, Bristol-Myers Squibb When the parties engaged in correspondence, Teva refused to divulge its launch plans as it considered these plans confidential. [read post]
15 Dec 2020, 5:00 am
Supreme Court opinions, the most recent of which was in the case of Bristol-Myers Squibb v. [read post]
13 Feb 2013, 11:49 pm
For those interested, the Indian patent number is 213457 and the case details are: Bristol-Myers Squibb Company v. [read post]
15 Apr 2010, 4:27 am
(EPLAW) Prevacid (Lansoprazole) – US: Takeda files patent infringement complaint against Zydus following Para IV challenge (Patent Docs) Reyataz (Atazanavir) – US: Bristol-Myer Squibb, Novartis file patent infringement suit against Teva following Para IV challenge (Patent Docs) Treximet (Sumatriptan, Naproxen) – US: POZEN enters into settlement agreement with Teva regarding Para IV patent litigation (SmartBrief) Zerit (Stavudine) – US: Promote… [read post]
28 Oct 2007, 7:21 pm
Cir. 2007) In the early 1990s, Bristol-Myers Squibb developed and patented Megace, a liquid pharmaceutical composition of megestrol acetate indicated for the treatment of anorexia, cachexia, or an unexplained weight loss. [read post]
16 Sep 2016, 4:07 am
Previously, the Full Court in Bristol-Myers Squibb Company v Apotex Pty Ltd [2015] FCAFC 2 (BMS) upheld Justice Yates’ ruling at first instance that the grant of an ‘exclusive licence’ meant an exclusive licence to undertake all of the activities within the meaning of “exploit” as defined in the Patents Act. [read post]
25 Apr 2010, 5:52 pm
Bristol-Myers Squibb Co. [read post]
18 Dec 2007, 6:35 am
Also, previous holdings from the CAFC (Bristol-Myers Squibb Co. v. [read post]
25 Feb 2013, 2:39 pm
Bristol Myers Squibb Co., No. 2013 U.S. [read post]
16 Feb 2011, 12:04 am
It looks like they would also do away with all the problems of the “threshold” requirement introduced by Phillips v Mirabella (the nature of the problem is laid out at paragraphs 19 to 27 of Bristol-Myers Squibb v Faulding). [read post]
17 Feb 2017, 12:21 pm
Bristol-Myers Squibb Co. v. [read post]
6 May 2013, 4:33 pm
Thus, reciting Bristol-Myers Squibb Co. v Ben Venue Labs. [read post]
24 Jan 2007, 9:59 pm
It was also recently reported that Lek D.D., a subsidiary of Sandoz, filed a complaint for patent infringement against Bristol-Myers Squibb and Watson Pharmaceuticals relating to BMS's Pravachol (pravastatin sodium). [read post]
13 Feb 2015, 12:00 pm
That case alleged that AstraZeneca and Bristol-Myers Squibb paid disguised, undisclosed rebates, fees and grants to Medco for purchasing their drugs while inaccurately reporting pricing information to the government. [read post]
10 Dec 2010, 3:06 am
Inc., 2000 US Dist LEXIS 21316, *12-13 [2000]; Grant v Bristol-Myers Squibb, 97 F Supp 2d 986, 992 [2000]). [read post]
15 Jan 2009, 3:35 am
Just to recap then, the High Court of Delhi recently granted an ex parte restraining order in favour of Bristol Myers Squibb restraining the defendants, Hetero Drugs (an Indian generic firm) from manufacturing, selling, distributing, advertising, exporting, offering for sale or in any manner dealing directly or indirectly in any product infringing the plaintiffs product patent covering Dasatinib, a drug used in the treatment of Chronic Myloeid Leukemia. [read post]
24 Jan 2013, 11:49 am
Bristol-Myers Squibb Co., No. 06-6050 (FLW) (D.N.J. [read post]
